Table 1

Sensitivity and specificity of EC4d, BC4d, TC4 and PC4d

CB-CAPs	Sensitivity (%)	Specificity	Reference
EC4d	70	83.1% versus other rheumatic diseases 92.7% versus NHV	Kalunian et al, 201248
	24	96% versus primary fibromyalgia	Wallace et al, 201618
	46	88%–95% versus other rheumatic diseases 99% versus NHV	Putterman et al, 201414
BC4d	60	82% versus other autoimmune or inflammatory diseases	Liu et al, 200949
	33	100% versus primary fibromyalgia	Wallace et al, 201618
	65.7	86.5% versus other rheumatic diseases 95.6% versus NHV	Kalunian et al, 201248
	53	90%–96% versus other rheumatic diseases 99% versus NHV	Putterman et al, 201414
TC4d	56	80% versus other autoimmune or inflammatory diseases	Liu et al, 200949
PC4d	46.2	92.7% versus other rheumatic diseases 99.5% versus NHV	Kalunian et al, 201248
	18	98% versus other rheumatic diseases 100% versus NHV	Navratil et al, 200633
	48	96% versus NHV	Lood et al, 201235

CB-CAP, cell-bound complement activation product; NHV, normal healthy volunteers.